Press releases
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
- Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
- Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
- Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
- Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
As of last trade Sarepta Therapeutics Inc (AB3A:BRN) traded at 108.74, -8.06% below its 52-week high of 118.27, set on Feb 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 108.74 |
---|---|
High | 108.74 |
Low | 108.74 |
Bid | 107.44 |
Offer | 108.15 |
Previous close | 108.74 |
Average volume | -- |
---|---|
Shares outstanding | 93.86m |
Free float | 89.37m |
P/E (TTM) | -- |
Market cap | 12.22bn USD |
EPS (TTM) | -6.15 USD |
Data delayed at least 15 minutes, as of Mar 06 2024.
More ▼